Tcr2 Therapeutics Inc (NASDAQ:TCRR) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 626,700 shares, a growth of 209.8% from the June 30th total of 202,300 shares. Based on an average daily volume of 50,700 shares, the short-interest ratio is currently 12.4 days. Approximately 7.5% of the company’s shares are sold short.
Shares of TCRR stock traded up $0.81 during trading hours on Monday, reaching $16.09. 31,767 shares of the stock were exchanged, compared to its average volume of 49,381. The stock has a fifty day moving average price of $14.13. Tcr2 Therapeutics has a 12-month low of $10.04 and a 12-month high of $25.47. The stock has a market cap of $375.86 million and a price-to-earnings ratio of -0.16.
Tcr2 Therapeutics (NASDAQ:TCRR) last released its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.11. Equities analysts predict that Tcr2 Therapeutics will post -6.12 EPS for the current fiscal year.
TCRR has been the subject of a number of recent analyst reports. Roth Capital initiated coverage on Tcr2 Therapeutics in a report on Friday, May 31st. They set a “neutral” rating and a $16.00 price target for the company. Zacks Investment Research upgraded Tcr2 Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Finally, ValuEngine upgraded Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Tcr2 Therapeutics presently has an average rating of “Buy” and an average price target of $27.80.
Tcr2 Therapeutics Company Profile
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Further Reading: Bar Chart
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.